Abbott Laboratories $ABT Shares Bought by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. boosted its position in shares of Abbott Laboratories (NYSE:ABT) by 14.4% in the third quarter, Holdings Channel reports. The fund owned 368,095 shares of the healthcare product maker’s stock after purchasing an additional 46,248 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Abbott Laboratories were worth $36,379,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. boosted its position in Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares during the last quarter. State Street Corp increased its position in shares of Abbott Laboratories by 1.7% during the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Abbott Laboratories during the 2nd quarter valued at about $1,603,607,000. Deutsche Bank AG increased its position in shares of Abbott Laboratories by 18.6% during the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock valued at $1,515,963,000 after purchasing an additional 2,614,965 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Abbott Laboratories in the 2nd quarter worth approximately $1,082,524,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research reports. Rothschild & Co Redburn raised shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $119.00 to $127.00 in a report on Friday, October 2nd. Wells Fargo & Company upped their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a research report on Thursday, August 13th. JPMorgan Chase & Co. increased their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, Robert W. Baird began coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $118.88.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $100.59 on Thursday. The stock has a market cap of $174.06 billion, a PE ratio of 32.55, a price-to-earnings-growth ratio of 1.90 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02. The firm has a fifty day moving average price of $105.47 and a 200-day moving average price of $98.28. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.42. The company had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.30 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.53 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter adjusted earnings per share were $1.42, in line with the company’s consensus estimate, while revenue rose 14.5% year over year to $13.01 billion, slightly exceeding expectations. Comparable sales increased 7%, and Abbott reaffirmed its full-year adjusted EPS guidance. Abbott third-quarter results
• Positive Sentiment: Management announced plans to separate its approximately $8.5 billion Nutrition business—including Ensure, Similac, Glucerna, Pedialyte and PediaSure—into an independent, publicly traded company through a tax-free distribution to shareholders, targeted for completion by the end of 2027. Abbott believes the transaction could accelerate growth and expand margins in its remaining businesses. Abbott Nutrition separation announcement
• Positive Sentiment: New product approvals and European authorization for Abbott’s Cologuard Plus colorectal cancer test expand its diagnostics portfolio and could support longer-term growth. Cologuard Plus European approval
• Neutral Sentiment: The spin-off is intended to unlock value by allowing Abbott and the new Nutrition company to pursue separate strategies, but investors must assess execution, tax and transition risks before the separation is completed.
• Negative Sentiment: Abbott lowered its 2026 sales-growth forecast, citing weakness in medical devices. The reduced outlook suggests near-term operating momentum may be softer than previously expected, despite continued strength in areas such as continuous glucose monitoring. Reuters report on Abbott’s outlook
• Negative Sentiment: Some analysts characterized the $1.42 adjusted EPS result as a slight miss against a $1.43 estimate. Combined with the lower sales outlook and uncertainty surrounding the Nutrition separation, that has outweighed the quarter’s revenue growth and caused the stock to decrease.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.